Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases is a phase 2, randomised interventional study registered as NCT04899908 by Brigham and Women's Hospital, with a registry enrolment figure of 134 participants, started 2021-09-15 and due to reach its primary completion in 2028-04. Interventions recorded: Stereotactic Radiation; AGuIX gadolinium-based nanoparticles; Placebo. Conditions listed: Brain Cancer; Brain Metastases; Melanoma; Lung Cancer; Breast Cancer; HER2-positive Breast Cancer; Colorectal Cancer; Gastrointestinal Cancer; SRS; SRT; Whole Brain Radiation; Stereotactic Radiation; AGuIX; Nanoparticle; Cystic; Brain Tumor. Primary outcome: Local Recurrence. Colorectal eligibility wording from the registry: "* Locally recurrent metastases after prior whole brain radiation \*Patients with metastases from melanoma, GI primaries, or HER2+ breast cancer, as well as those with cystic metastases or metastases ≥2cm in maximal unidimensional size, who have local recurrences after prior brain-directed radiation ". Sites: United States. No results are recorded here; the registry entry is the source.